Epothilones: a noel class of microtubule-stabilizing drugs for the treatment of cancer

被引：27
作者：
Trivedi, Meghana [1 ]
Budihardjo, Imawati [1 ]
Loureiro, Kirsten [1 ]
Reid, Tony R. [1 ]
Ma, Joseph D. [1 ]
机构：
[1] Univ Calif San Diego, Moores Canc Ctr, Skaggs Sch Pharm & Pharmaceut Sci, La Jolla, CA 92093 USA
来源：
FUTURE ONCOLOGY | 2008年 / 4卷 / 04期
关键词：
beta-tubulin; epothilone; ixabepilone; metastatic breast cancer; microtubule; P-glycoprotein;
D O I：
10.2217/14796694.4.4.483
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Microtubule-targeted anticancer drugs are effective in treating various cancers but are limited in use due to development of resistance and unacceptable toxicities. The epothilones are a novel class of microtubule-stabilizing anticancer drugs and may have a role in treating taxane-resistant cancers. Revised and updated data from several clinical studies for ixabepilone were recently published and subsequently resulted in ixabepilone becoming the first epothilone approved as monotherapy or in combination for treatment of locally advanced or metastatic breast cancer. BMS-310705, patupilone, KOS-862, KOS-1584 and ZK-EPO are epothilones that have been developed. Although peripheral sensory neuropathy and neutropenia are the dose-limiting toxicities for ixabepilone, these dose-limiting toxicities are ixabepilone specific. This review will discuss the current preclinical, clinical pharmacokinetic and pharmacodynamic, efficacy and toxicity data of the epothilones.
引用
收藏
页码：483 / 500
页数：18
相关论文
共 152 条
  • [1] Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five days
    Abraham, J
    Agrawal, M
    Bakke, S
    Rutt, A
    Edgerly, M
    Balis, FM
    Widemann, B
    Davis, L
    Damle, B
    Sonnichsen, D
    Lebwohl, D
    Bates, S
    Kotz, H
    Fojo, T
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (09) : 1866 - 1873
  • [2] ABREY L, 2007, ASCO ANN M CHIC IL U
  • [3] Aghajanian C, 2007, J CLIN ONCOL, V25, P1082, DOI 10.1200/JCO.2006.08.7304
  • [4] Treatment of recurrent cervical adenocarcinoma with BMS-247550, an epothilone B analog
    Agrawal, M
    Edgerly, M
    Fojo, T
    Kotz, H
    [J]. GYNECOLOGIC ONCOLOGY, 2003, 90 (01) : 96 - 99
  • [5] AGRAWAL N, 2003, ASCO ANN M CHIC IL U
  • [6] A multi-center phase II study of BMS-247550 (Ixabepilone) by two schedules in patients with metastatic gastric adenocarcinoma previously treated with a taxane
    Ajani, J. A.
    Safran, H.
    Bokemeyer, C.
    Shah, M. A.
    Lenz, H. -J.
    Van Cutsem, E.
    Burris, H. A., III
    Lebwohl, D.
    Mullaney, B.
    [J]. INVESTIGATIONAL NEW DRUGS, 2006, 24 (05) : 441 - 446
  • [7] Epothilones and related structures - a new class of microtubule inhibitors with potent in vivo antitumor activity
    Altmann, KH
    Wartmann, M
    O'Reilly, T
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2000, 1470 (03): : M79 - M91
  • [8] The merger of natural product synthesis and medicinal chemistry: on the chemistry and chemical biology of epothilones
    Altmann, KH
    [J]. ORGANIC & BIOMOLECULAR CHEMISTRY, 2004, 2 (15) : 2137 - 2152
  • [9] ANDERSON S, 2004, ASCO ANN M LOS ANG C
  • [10] ANTHONY L, 2003, ASCO ANN M CHIC IL U
12345678910